Pfizer's Bourla: Chinese drugmakers will be my main rivals by 2030
Pfizer CEO Albert Bourla told the Jefferies conference that Chinese drugmakers, not AstraZeneca or Eli Lilly, will be his main competition by 2030 — and AI is his only lever to match their cost and speed.
TAG T-7393 · 562 words on the filing

Summary of findings
- Pfizer CEO Albert Bourla named Chinese companies, not AstraZeneca or Eli Lilly, as his main competition by 2030, speaking on 17 November.
- China's 15th five-year plan targets 25% of global first-in-class drugs developed domestically by 2030.
- 2026 licensing deals include AstraZeneca's $18.5bn obesity pact with CSPC (January) and BMS's $15.2bn deal with Jiangsu Hengrui (May).
- Bourla said Chinese rivals operate at half the cost and three to four times the speed, calling AI Pfizer's biggest lever to compete.
- The US Treasury proposed adding biotech to the COINS Act last month, on top of the BIOSECURE Act already in force this year.
Pfizer CEO Albert Bourla says Chinese companies will overtake AstraZeneca and Eli Lilly as his biggest competitive threat by 2030. He set out the forecast at the Jefferies Global Healthcare Conference in London on 17 November.
"By 2030, they will represent my major competition. It's not going to be AstraZeneca or Eli Lilly. It's going to be Chinese companies," Bourla told the audience.
Why does Bourla see China as the next rival?
China has moved beyond its old role as a licensing destination. In September, Beijing unveiled the 15th five-year plan for its biomedical industry, which aims to make the country more proactive on the global stage. The plan sets a hard target: by 2030, China wants to make and develop 25% of global first-in-class drugs. The government explicitly wants to become an exporter of innovative drugs rather than a supplier of active pharmaceutical ingredients (APIs).
"China [is] growing its biotech business and has an ambition to become a global player. I think they will be successful," Bourla said.
How big is the licensing flow already?
Over the past decade, China has become a go-to port of call for Western big pharma hunting pipeline additions. GlobalData, parent company of Pharmaceutical Technology, reports that licensing deals between US and Chinese biopharma companies have risen sharply in recent years — and its analysts estimate another deal inflexion is coming, though 2026 analysis is still pending.
The 2026 deal sheet backs that up:
- AstraZeneca struck an $18.5bn obesity deal with CSPC in January 2026.
- Bristol Myers Squibb signed a $15.2bn deal with Jiangsu Hengrui Pharma in May 2026.
Can Pfizer match China's cost and speed?
Bourla put the gap in blunt numbers. "They are coming in at half the cost, and three or four times the speed. If we want to compete with them by 2030, we need to be half the cost, and increase speed by three or four times," he said.
He conceded that target looks daunting without a step change in R&D productivity. "That sounds very difficult to achieve, unless AI delivers on the problems. And AI, for me, is the biggest lever to be able to build the Pfizer for the future," Bourla added.
President Xi Jinping has outlined initiatives to back the push: R&D spending will ramp up, AI and quantum computing will feed drug discovery, and pharma ecosystems will extend beyond pipelines alone.
What does Washington's tightening mean?
Bourla's comments land amid regulatory flux that shapes how Western pharma deals with Chinese biotechs. Last month, the US Department of the Treasury proposed adding biotech to the Comprehensive Outbound Investment Security (COINS) Act. That framework widens government power to restrict or monitor US investment in sensitive technologies held by companies listed as "ones of concern" — a category widely read as targeting American investment in China.
Biotech's potential COINS inclusion stacks onto an already strained relationship. The BIOSECURE Act came into law this year, blocking Chinese biotechs and manufacturers from accessing US funding or collaborating with domestic pharma companies using federal dollars.
Then, in November, the midterms handed Democrats both the Senate and the House. Analysts expect near-term pharma dynamics to stay largely unchanged, but the shift sharpens congressional focus on Trump administration policies — China-directed investment among them, plus Most Favored Nation (MFN) drug-pricing deals.
via Pharmaceutical Technology (Source)
More from Marcus Bennett
Show full bio
News editor covering regulation, policy and their impact on global pharmaceutical industry at PharmInsider.
6 articles
Linked filings
- T-4813
- K-2547
- E-6700
- E-9238
- E-2578